Nykode Therapeutics AS (OTCMKTS:VACBF – Get Free Report) was the target of a significant increase in short interest in June. As of June 15th, there was short interest totaling 980 shares, an increase of ? from the May 31st total of 0 shares. Based on an average daily volume of 367 shares, the short-interest ratio is currently 2.7 days.
Nykode Therapeutics AS Price Performance
Shares of VACBF stock opened at $0.32 on Thursday. The stock’s fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.32. Nykode Therapeutics AS has a fifty-two week low of $0.32 and a fifty-two week high of $0.36.
Nykode Therapeutics AS Company Profile
Nykode Therapeutics AS (OTCMKTS:VACBF) is a clinical-stage biotechnology company based in Oslo, Norway, focused on the development of precisely targeted immunotherapies. The company’s proprietary platform is designed to deliver antigenic payloads directly to antigen-presenting cells, with the goal of eliciting potent and durable immune responses against both cancerous and infectious disease targets. By combining modular antigen design with novel delivery modalities, Nykode aims to drive next-generation vaccine and immunotherapy solutions.
The company’s clinical pipeline includes several lead candidates in oncology and infectious diseases.
Read More
- Five stocks we like better than Nykode Therapeutics AS
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Nykode Therapeutics AS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nykode Therapeutics AS and related companies with MarketBeat.com's FREE daily email newsletter.
